Table
4: Primary and
secondary outcomes based on HBP# and CBP## measured at
end-point in 116 obese patients with type 2 diabetes mellitus.
Outcome |
Patient
status: HBP* at end-point in 116 obese patients |
Patient
status: CBP** at end-point in 116 obese patients |
|||||||
Hypertension |
Normotension |
Hazard
ratio |
P |
Hypertension |
Normotension |
Hazard
ratio |
P |
||
(n = 73) |
(n = 43) |
(95% CI) |
|
(n = 54) |
(n = 62) |
(95% CI) |
|||
Primary outcome |
|||||||||
Death |
20 |
5 |
0.4 (0.2–1.0) |
0.0500 |
13 |
11 |
2.4 (1.0-5.0) |
0.4904 |
|
Secondary outcome |
|||||||||
Microvascular
complications |
46 |
25 |
1.4 (1.0–2.5) |
0.1085 |
34 |
37 |
0.9 (0.5-1.7) |
0.7110 |
|
Macrovascular
complications |
20 |
5 |
2.6 (1.0–5.1) |
0.0463 |
13 |
12 |
1.2 (0.6-2.7) |
0.5810 |
|
The obesity was
defined by as the definition of the criteria of Japan Society for the Study of
Obesity. Body mass Index (BMI) with ≧ 25.0 kg/m2 was defined as obesity. The 400
patients in each group were classified as having obesity and hypertension or normotension according to values of blood pressure as
recent guidelines show normotensions are less than
125 mm Hg measured in the home (HBP#) and less than 130 mmHg
measured in the clinic (CBP##) at end-point, respectively.
Differences in primary and secondary outcomes for events between obese patients
with hypertension and normotension measured at
end-point in each group were assessed using survival curves from the
Kaplan-Meier method, and comparisons were analyzed
using hazard ratio by the log-rank test. CI, confidence interval. Two-tailed
values of P < 0.05 were defined as statistically significant.